0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAP (TGF-beta 1)

LAP (TGF-beta 1)

LAP (TGF-beta 1) Molecule Information

Name:Transforming growth factor beta 1
Target Synonym:TGFbeta?Transforming Growth Factor Beta 1?Diaphyseal Dysplasia 1? Progressive?TGF-Beta1?IBDIMDE?Transforming Growth Factor beta1?Latency-Associated Peptide?TGFB?CED?DPD1?Transforming Growth Factor? Beta 1?TGF-Beta-1?Prepro-Transforming Growth Factor Beta-
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:10
Lastest Research Phase:Approved

LAP (TGF-beta 1) Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
LAP-H82Q6 Human Biotinylated Human LAP (TGF-beta 1) Protein, His,Avitag™
LAP-H82Q6-structure
LAP-H82Q6-sds
LAP-H82Q6-elisa_1
LAP-H5245 Human Human LAP (TGF-beta 1) Protein, His Tag
LAP-H5245-structure
LAP-H5245-sds
LAP-H5245-elisa_1

LAP (TGF-beta 1) Part of Bioactivity data

LAP-H5245-ELISA
Human LAP (TGF-beta 1), His TagHuman LAP (TGF-beta 1), His Tag (Cat. No. LAP-H5245) ELISA bioactivity

Immobilized Human LAP (TGF-beta 1), His Tag (Cat. No. LAP-H5245) at 2 μg/mL (100 μL/well) can bind Biotinylated Human ITGAV&ITGB6 Heterodimer Protein, His,Avitag&Tag Free (Cat. No. IT6-H82E4) with a linear range of 0.8-25 ng/mL (QC tested).

LAP-H82Q6-ELISA
Biotinylated Human LAP (TGF-beta 1), His,AvitagBiotinylated Human LAP (TGF-beta 1), His,Avitag (Cat. No. LAP-H82Q6) ELISA bioactivity

Immobilized Human ITGAV&ITGB6 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT6-H52E1) at 5 μg/mL (100 μL/well) can bind Biotinylated Human LAP (TGF-beta 1), His,Avitag (Cat. No. LAP-H82Q6) with a linear range of 0.4-6 ng/mL (QC tested).

LAP (TGF-beta 1) Molecule Synonym Name

LAP (TGF-beta 1),TGFB1,CED,DPD1,LAP,TGF-beta-1,TGFB

LAP (TGF-beta 1) Molecule Background

Transforming growth factor beta 1 ( TGFB1) is also known as TGF-?1, CED, DPD1, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis.  The TGFB1 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB1 protein is found throughout the body and plays a role in development before birth, the formation of blood vessels, the regulation of muscle tissue and body fat development, wound healing, and immune system function. TGFB1 is particularly abundant in tissues that make up the skeleton, where it helps regulate bone growth, and in the intricate lattice that forms in the spaces between cells (the extracellular matrix). Within cells, this protein is turned off (inactive) until it receives a chemical signal to become active. TGFB1 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages. Most immune cells (or leukocytes) secrete TGFB1. TGFB1 has been shown to interact with TGF beta receptor 1, LTBP1, YWHAE, EIF3I  and Decorin.

LAP (TGF-beta 1) References

LAP (TGF-beta 1) Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Pirfenidone F-647; AMR-69; GP-101; S-7701; S-770108; RO-0220912 Approved Intermune 艾思瑞, Deskar, Etuary, Esbriet, Pirespa, Aisuryui United States Idiopathic Pulmonary Fibrosis s:13:"Genentech Inc"; 2008-10-16 Radiation Pneumonitis; Renal Insufficiency; Dermatomyositis; Idiopathic Pulmonary Fibrosis; Scleroderma, Systemic; Pulmonary Fibrosis; Lung Diseases, Interstitial; Diabetic Nephropathies; Alveolitis, Extrinsic Allergic; Pneumoconiosis Details

LAP (TGF-beta 1) Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Nicousamide XLF-III-43 Phase 2 Clinical Institue Of Materia Medica Chinese Academy Of Medical Science Hypertensive nephropathy; Diabetic Nephropathies Details
盐酸美氟尼酮 Phase 1 Clinical Guangzhou Nanxin Pharmaceutical Co Ltd, Central South University Diabetic Nephropathies Details
DW-1029M DW-1029M Phase 2 Clinical Dong Wha Pharmaceuticals Diabetic Nephropathies Details
Disitertide P-144; NAFB-001; Peptide-144 Phase 2 Clinical Digna Biotech, University Of Navarra Fibrosis; Scleroderma, Systemic Details
Fluorofenidone AKF-PD Phase 1 Clinical Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University Liver Cirrhosis; Renal fibrosis Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
YL-13027 YL-13027 Phase 1 Clinical Shanghai Yingli Pharmaceutical Co Ltd Solid tumours Details
STP-705 STP-705; STP-705L; STP-705LU; STP-705LV Phase 2 Clinical Suzhou Shengnuo Biological Medicine Technology Co Ltd, Sirnaomics Liver Neoplasms; Bowen's Disease; Carcinoma, Basal Cell; Cholangiocarcinoma; Carcinoma, Squamous Cell; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular Details
Vactosertib EW-7197; NOV-1301; TEW-7197 Phase 2 Clinical Medpacto Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Urologic Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
Yinfenidone Hydrochloride HEC-585; HEC-00000585 Phase 2 Clinical Hec Pharm Co Ltd Idiopathic Pulmonary Fibrosis Details

This web search service is supported by Google Inc.

totop